Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis
- 9 October 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 26 (6) , 613-621
Abstract
Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and psychosocial comorbidities decreasing the quality of life for many patients. Dupilumab, a human monoclonal antibody that blocks interleukins IL-4 and IL-13, is a recently added systematic treatment option with an emerging evidence base. Here, we assessed the safety and efficacy of dupilumab in patients with AD. We conducted a systematic review and meta-analysis of placebo-controlled randomized clinical trials evaluating the safety and efficacy of dupilumab on AD-related outcomes including clinical symptoms, quality of life and adverse events (AE). Subgroup analysis was further performed in adults and children/adolescents. Fourteen trials were included: twelve in adults (n = 3,817) and two in children/adolescents (n = 618). Dupilumab decreased the Eczema Area Severity Index (EASI) score [standardized mean difference (SMD) = −0.98; 95% confidence interval (95% CI) = (−1.09, −0.88)], the percent change difference in Scoring Atopic Dermatitis (SCORAD) [mean difference (MD) = −31.56, 95% CI = (−33.75, −29.36)], and in pruritus Numeric Rating Scale (pNRS) [MD = −29.24, 95% CI = (−32.11, −26.37)]. It also achieved a reduction of at least ≥75% in the EASI score [Risk Ratio (RR) = 2.89, 95% CI = (2.47, 3.38)], the Investigator’s Global Assessment (IGA) score ≤1 [RR = 3.47, 95% CI = (2.96, 4.06)] and eight additional endpoints with no signs of increased AE compared to placebo. In subgroup analysis, the results were concordant for both groups. Dupilumab improved clinical symptoms and quality of life in adults and children/adolescents with a safety profile comparable to placebo.Keywords
This publication has 34 references indexed in Scilit:
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- New era of biologic therapeutics in atopic dermatitisExpert Opinion on Biological Therapy, 2013
- Impacto de la calidad de vida relacionada con la salud en población pediátrica y adulta española con dermatitis atópica. Estudio PSEDAActas Dermo-Sifiliograficas, 2013
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- A Re-Evaluation of Random-Effects Meta-AnalysisJournal of the Royal Statistical Society Series A: Statistics in Society, 2008
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986